Table 1.
Baseline Characteristics of Discovery and Validation Cohorts
| Characteristic | Discovery Cohort (PHIV) | Validation Cohort 1 (PHIV) | Validation Cohort 1 (PHEU) | Validation Cohort 2 (PHIV) |
|---|---|---|---|---|
| Number | 464 | 394 | 214 | 357 |
| Female, No. (%) | 236 (50.9) | 216 (53.4) | 103 (48) | 192 (53.8) |
| Race/ethnicity, No. (%)a | ||||
| Hispanic | 123 (26.5) | 100 (25.4) | 76 (36.0) | 120 (33.6) |
| Black | 286 (61.6) | 279 (70.8) | 132 (61.7) | 190 (53.2) |
| White | 51 (11) | 89 (22.6) | 73 (34.1) | 44 (12.3) |
| Unknown/other | 4 (0.9) | 26 (6.6) | 9 (4.2) | 3 (.80.8) |
| CD4+, count/mm3, median (Q1, Q3) | 859 (416, 1490) | 730 (522, 953) | NA | 668 (466, 924) |
| Log HIV RNA, median (Q1, Q3) | 5.4 (4.7, 6.0) | 2.5 (1.7, 3.1) | NA | 4.2 (3.6, 4.7) |
| Age, y, median (Q1, Q3) | 1.5 (0.7, 3.6) | 12 (9, 14) | 10 (8, 11) | 6 (5, 9) |
| CSA, median (Q1, Q3) | 71.5 (58, 89) | 86 (75, 95) | 87 (78, 99) | 83 (74, 93) |
| CSA < 70, No. (%) | 217 (46.8) | 54 (13.7) | 24 (11.2) | 54 (15.1) |
| CSA ≥ 70, No. (%) | 247 (53.2) | 340 (86.3) | 190 (88.8) | 303 (84.9) |
Abbreviations: CSA, cognitive score for age; NA, not available; PHEU, perinatally HIV exposed uninfected; PHIV, perinatally HIV infected.
aRace and ethnicity were reported from a single question for the discovery cohort and validation cohort 2. Hispanic ethnicity and race were reported as 2 separate questions for validation cohort 1.